Keywords: seragen, files, bla, t-cell, lymphoma, drug, submitted
Seragen Files BLA For T-Cell Lymphoma Drug
Article | 18 December 1997
Seragen has submitted a Biologics License Application to the US Food andDrug Administration requesting approval to market DAB389IL-2 (denileukin ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
